BACKGROUND: Circulating levels of soluble urokinase-like plasminogen activator receptor (suPAR) have been associated with proteinuria and renal function in focal segmental glomerulosclerosis (FSGS). This study aimed to evaluate if circulating suPAR levels are independently associated with proteinuria in patients with non-FSGS glomerulonephritis. METHODS: This is a cross-sectional analysis of suPAR levels on 42 patients with primary non-FSGS glomerulonephritis (group GN) and 140 patients with secondary glomerulonephritis within an autoimmune disease (group AID). RESULTS: suPAR serum levels were significantly higher in AID patients (4,733 ± 3,073 pg/ml) than in healthy controls (1,908 ± 1,685 pg/ml; p < 0.001), whereas GN patients displayed intermediate levels (3,670 ± 2,435 pg/ml; p = 0.021). Multivariate analysis for elevated serum suPAR (>3,000 pg/ml) showed an independent association with estimated glomerular filtration rate (eGFR) <60 ml/min/1.73 m(2) [odds ratio (OR) = 4.19, 95% confidence interval (CI): 1.67-10.54, p = 0.002], proteinuria >0.5 g/day (OR = 2.97; 95% CI: 1.32-6.70; p = 0.009) and presence of secondary vs. primary GN (OR = 2.87, 95% CI: 1.25-6.23; p = 0.013). A general linear model confirmed that suPAR levels were significantly affected by proteinuria >0.50 g/day (coefficient +1,477 pg/ml), eGFR (-38 pg/ml per 1 ml/min/1.73 m(2) increase) and presence of secondary vs. primary GN (+1,368 pg/ml). CONCLUSIONS: This study shows that elevated serum suPAR levels are associated with reduced eGFR and presence of proteinuria in both primary and secondary GN, suggesting that circulating suPAR may represent a common biomarker of renal involvement in a wide spectrum of GN.
BACKGROUND: Circulating levels of soluble urokinase-like plasminogen activator receptor (suPAR) have been associated with proteinuria and renal function in focal segmental glomerulosclerosis (FSGS). This study aimed to evaluate if circulating suPAR levels are independently associated with proteinuria in patients with non-FSGS glomerulonephritis. METHODS: This is a cross-sectional analysis of suPAR levels on 42 patients with primary non-FSGS glomerulonephritis (group GN) and 140 patients with secondary glomerulonephritis within an autoimmune disease (group AID). RESULTS:suPAR serum levels were significantly higher in AIDpatients (4,733 ± 3,073 pg/ml) than in healthy controls (1,908 ± 1,685 pg/ml; p < 0.001), whereas GN patients displayed intermediate levels (3,670 ± 2,435 pg/ml; p = 0.021). Multivariate analysis for elevated serum suPAR (>3,000 pg/ml) showed an independent association with estimated glomerular filtration rate (eGFR) <60 ml/min/1.73 m(2) [odds ratio (OR) = 4.19, 95% confidence interval (CI): 1.67-10.54, p = 0.002], proteinuria >0.5 g/day (OR = 2.97; 95% CI: 1.32-6.70; p = 0.009) and presence of secondary vs. primary GN (OR = 2.87, 95% CI: 1.25-6.23; p = 0.013). A general linear model confirmed that suPAR levels were significantly affected by proteinuria >0.50 g/day (coefficient +1,477 pg/ml), eGFR (-38 pg/ml per 1 ml/min/1.73 m(2) increase) and presence of secondary vs. primary GN (+1,368 pg/ml). CONCLUSIONS: This study shows that elevated serum suPAR levels are associated with reduced eGFR and presence of proteinuria in both primary and secondary GN, suggesting that circulating suPAR may represent a common biomarker of renal involvement in a wide spectrum of GN.
Authors: Björn Meijers; Rutger J H Maas; Ben Sprangers; Kathleen Claes; Ruben Poesen; Bert Bammens; Maarten Naesens; Jeroen K J Deegens; Ruth Dietrich; Markus Storr; Jack F M Wetzels; Pieter Evenepoel; Dirk Kuypers Journal: Kidney Int Date: 2014-01-08 Impact factor: 10.612
Authors: T K Outinen; S Mäkelä; R Huttunen; N Mäenpää; D Libraty; A Vaheri; J Mustonen; J Aittoniemi Journal: J Intern Med Date: 2014-05-14 Impact factor: 8.989
Authors: Carlos R Franco Palacios; John C Lieske; Hani M Wadei; Andrew D Rule; Fernando C Fervenza; Nikolay Voskoboev; Vesna D Garovic; Ladan Zand; Mark D Stegall; Fernando G Cosio; Hatem Amer Journal: Transplantation Date: 2013-08-27 Impact factor: 4.939
Authors: Shengyuan Luo; Josef Coresh; Adrienne Tin; Casey M Rebholz; Teresa K Chen; Salim S Hayek; Melissa Tracy; Michael S Lipkowitz; Lawrence J Appel; Andrew S Levey; Lesley A Inker; Jochen Reiser; Morgan Erika Grams Journal: Clin J Am Soc Nephrol Date: 2018-06-14 Impact factor: 8.237
Authors: Jiwon M Lee; Jae Won Yang; Andreas Kronbichler; Michael Eisenhut; Gaeun Kim; Keum Hwa Lee; Jae Il Shin Journal: J Immunol Res Date: 2019-04-04 Impact factor: 4.818
Authors: Reem M Ahmed; Mona A Khalil; Amal H Ibrahim; Hanaa M Eid; Walid Kamal Abdelbasset; Gaber S Soliman Journal: Medicine (Baltimore) Date: 2019-09 Impact factor: 1.817